FDA Experts Are Still Puzzled Over Who Should Get Which Covid Shots and When
A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.
Is Legislation to Safeguard Americans Against Superbugs a Boondoggle or Breakthrough?
While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.
Pfizer’s Covid Cash Powers a ‘Marketing Machine’ on the Hunt for New Supernovas
While sales of its covid vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.
$38,398 for a Single Shot of a Very Old Cancer Drug
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?
Pharma-Funded FDA Gets Drugs Out Faster, But Some Work Only ‘Marginally’ and Most Are Pricey
Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast.
Big Pharma Went All In to Kill Drug Pricing Negotiations
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn’t materialized.
Qué significa el caso de Nueva York para el fin de la polio
Para 2015, la polio se había erradicado casi por completo en todas partes excepto en Pakistán y Afganistán. Pero para 2020 se habían reportado casos en 34 países.
What the Polio Case in New York Tells Us About the End of Polio
The Rockland County case isn’t expected to cause a major outbreak, but it shows how even this rare disease can pop up in undervaccinated communities.
Boost Now or Wait? Many Wonder How Best to Ride Out Covid’s Next Wave
As the country faces a rise in new infections driven by the omicron BA.5 subvariant of the coronavirus, about 70% of people 50 and older who got a first covid-19 booster shot haven’t received the recommended second one, according to the Centers for Disease Control and Prevention. Many undervaccinated Americans have lost interest, and others aren’t sure whether to get boosted again now or wait for vaccines reformulated to target newer strains of the virus.
¿Ponerse el refuerzo ahora o esperar? Muchos se preguntan cómo navegar la próxima ola de covid
Aproximadamente el 70% de los estadounidenses de 50 años o más que recibieron una primera vacuna de refuerzo contra covid, y casi la misma cantidad de personas de 65 años o más, no han recibido un segundo, según datos de los CDC.